⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
BBIO News
BridgeBio Pharma, Inc. Common Stock
BridgeBio to Participate in November Investor Conferences
globenewswire.com
BBIO
BridgeBio to Present Data from the Overall ATTR-CM Variant and V142I (V122I) Populations from ATTRibute-CM at the AHA Scientific Sessions 2025
globenewswire.com
BBIO
BridgeBio Reports Third Quarter 2025 Financial Results and Business Updates
globenewswire.com
BBIO
BridgeBio Reports Positive Phase 3 Topline Results for Encaleret in Patients with Autosomal Dominant Hypocalcemia Type 1
globenewswire.com
BBIO
BridgeBio to Report Phase 3 Results for Encaleret in ADH1 CALIBRATE Study on Wednesday, October 29th
globenewswire.com
BBIO
BridgeBio Reports Positive Phase 3 Results for Small Molecule BBP-418 in LGMD2I/R9 FORTIFY Study
globenewswire.com
BBIO
BridgeBio to Report Phase 3 Results for Small Molecule BBP-418 in LGMD2I/R9 FORTIFY Study, along with Third Quarter 2025 Financial Results Next Week
globenewswire.com
BBIO
BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
globenewswire.com
BBIO
Acoramidis Begins to Reduce Cumulative Cardiovascular Outcomes Within the First Month of Treatment in Patients with ATTR-CM
globenewswire.com
BBIO